Objective       To analyze the efficacy and safety of combination of docetaxel and S-1 in the treatment of metastatic breast cancer (MBC).       Methods       Clinical data of 50 patients with MBC who had been administered docetaxel and S-1 between January 2008 and December 2010 in our hospital were retrospectively reviewed.       Results       The patients with complete remission partial remission

stable disease and progressive disease were 3

14

16 and 17 respectively. The overall response rate (ORR)

clinical benefit rate (CBR)

median time to treatment failure and overall survival of the 50 patients were 34.

0%

48.0%

163 d and 415 d respectively. Among the 16 patients in the first or the second line chemotherapy and the 34 patients in the third and later line chemotherapy

their ORR were 50.0% and 26.5% respectively

but CBR were 68.8% and 38.2% respectively

with significantly difference in CBR between the 2 groups (

P

<

0.05). For the 31 patients who had been treated with docetaxel and capecitabine

their ORR and CBR were 19.4% and 32.3% respectively. The majority of toxicity were granulopenia. Grade 4 events only accounted for 8%.       Conclusion       Combining docetaxel and S-1 is well-toleratable and safe for MBC patients

with promising efficiency and maintaining their quality of life. When applied in the early stage of MBC

the agents promise a very effective antitumor effect.